New hope for MSA patients: drug may reduce dizzy spells and falls

NCT ID NCT02071459

Completed Symptom relief Sponsor: University Hospital, Toulouse Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a drug called droxidopa (L-threo DOPS) in 107 adults with multiple system atrophy (MSA) who experience dizziness or fainting when standing up due to low blood pressure. Participants received either the drug or a placebo for 12 weeks. The goal was to see if the drug could reduce these symptoms and improve daily life. The trial is complete, and results help doctors understand if this treatment is helpful for managing this challenging symptom.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SYSTEM ATROPHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Hypotension, Orthostatic multiple system atrophy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE SYSTEM ATROPHY

Contacts and locations

Locations

CHRU de lille

Lille, 59037, France
CHU Pontchaillou

Rennes, 35033, France
CHU bordeaux

Bordeaux, France
CHU de Clermont-Ferrand

Clermont-Ferrand, 63000, France
CHU de Dijon

Dijon, 21000, France
CHU de Poitiers

Poitiers, 86021, France
CHU de Rouen

Rouen, 76031, France
CHU de limoges

Limoges, 87042, France
Centre hospitalier d'Angers

Angers, 49933, France
Hôpital G. & R. Laennec

Nantes, 44093, France
Hôpital La Timone

Marseille, 13000, France
Hôpital Pitié-Salpétrière

Paris, 75013, France
chu de Strasbourg

Strasbourg, 67091, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.